For migraine patients who suffer from 15 or more migraine days per month (chronic migraine) and/or those patients who suffer from long-lasting migraine attacks or do not experience sufficient relief with acute therapies, the greatest unmet need in migraine is for migraine prophylactic therapies with improved efficacy and tolerability than currently available therapies. Migraine prophylaxis was not the initial target of development for these therapies, resulting in drugs with sub-optimal efficacy, often only reducing migraine days by one or two days per month, and unfavorable side effects in a population that is generally otherwise healthy. Even in the highly genericized migraine prophylactic market, opportunity exists for branded therapies that offer greater efficacy and tolerability than currently available options.

Table of contents

  • Migraine - Unmet Need - Detailed, Expanded Analysis Migraine Prophylaxis
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in Migraine Prophylaxis
        • Importance of Efficacy Attributes to Prescribing Decisions in Migraine Prophylaxis — United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Migraine Prophylaxis — Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Migraine Prophylaxis — United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Migraine Prophylaxis — Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Migraine Prophylaxis — United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Migraine Prophylaxis — Europe
        • Importance of Non-Clinical Factors to Prescribing Decisions in Migraine Prophylaxis — United States
        • Importance of Non-Clinical Factors to Prescribing Decisions in Migraine Prophylaxis — Europe
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in Migraine Prophylaxis — United States
        • Stated Versus Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in Migraine Prophylaxis — Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Products for Migraine Prophylaxis
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for Migraine Prophylaxis — United States
        • Overall Performance of Key Therapies for Migraine Prophylaxis — Europe
        • Relative Performance of Key Therapies for Migraine Prophylaxis Across Select Efficacy Attributes — United States
        • Relative Performance of Key Therapies for Migraine Prophylaxis Across Select Efficacy Attributes — Europe
        • Relative Performance of Key Therapies for Migraine Prophylaxis Across Select Safety and Tolerability Attributes — United States
        • Relative Performance of Key Therapies for Migraine Prophylaxis Across Select Safety and Tolerability Attributes — Europe
        • Relative Performance of Key Therapies for Migraine Prophylaxis Across Select Convenience of Administration Attributes — United States
        • Relative Performance of Key Therapies for Migraine Prophylaxis Across Select Convenience of Administration Attributes — Europe
        • Relative Performance of Key Therapies for Migraine Prophylaxis Across Select Non-Clinical Attributes — United States
        • Relative Performance of Key Therapies for Migraine Prophylaxis Across Select Non-Clinical Attributes — Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Neurologists' Satisfaction With the Performance of Key Therapies for Migraine Prophylaxis on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — United States
        • Surveyed Neurologists' Satisfaction With the Performance of Key Therapies for Migraine Prophylaxis on Efficacy, Safety and Tolerability, Convenience of Administration, and Non-Clinical Factors — Europe
      • Physician Rating of Unmet Need in Migraine Prophylaxis
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Migraine Prophylaxis — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Migraine Prophylaxis — Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Migraine Prophylaxis — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Migraine Prophylaxis — Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Migraine Prophylaxis — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Migraine Prophylaxis — Europe
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Non-Clinical Factors in Migraine Prophylaxis — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need Across Key Non-Clinical Factors in Migraine Prophylaxis — Europe
      • Unmet Need in Migraine Prophylaxis and Related Indications
        • Surveyed Neurologists' Ascribed Level of Unmet Need in Migraine Prophylaxis and Related Indications — United States
        • Surveyed Neurologists' Ascribed Level of Unmet Need in Migraine Prophylaxis and Related Indications — Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Migraine Prophylactic Market and Emerging Therapy Insights
        • Opportunity: A New Therapy with Improved Efficacy on Measures of Migraine Frequency and Intensity
        • Opportunity: A New Prophylactic Therapy that Enhances Quality of Life for Migraine Patients
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • Migraine Prophylaxis Target Product Profile: Attribute Importance
        • Migraine Prophylaxis Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Migraine Prophylaxis Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • Migraine Prophylaxis Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • Migraine Prophylaxis Market Simulations: Target Product Profiles Included in Scenario 1
        • Migraine Prophylaxis Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • Migraine Prophylaxis Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • Migraine Prophylaxis Market Simulations: Target Product Profiles Included in Scenario 2
      • Abbreviations

    Author(s): Angela Sparrow, Ph.D.

    Angela Sparrow provides expert insight and authors primary market research and forecasting content as a member of the Central Nervous System and Ophthalmology Team. During her time with the company, Angela has extensively covered migraine, contributing to numerous reports while staying up-to-date on the latest trends and news. Additionally, she provides detailed responses to client inquiries and has authored content focused on psychiatric indications, including opioid addiction and depression, as well as neuropathic pain.

    Dr. Sparrow holds a Ph.D. in behavioral neuroscience from the University of North Carolina at Chapel Hill and a Bachelor’s degree from Northeastern University. Before joining DRG, she was a postdoctoral fellow at McLean Hospital, Harvard Medical School, studying the role of kappa opioid receptors in addiction and withdrawal-induced depression.


    Related Reports

    Migraine - Landscape & Forecast - Disease Landscape & Forecast

    The market for prescription migraine therapies comprises an array of

    View Details

    Migraine | Disease Landscape and Forecast | G7 | 2020

    The market for prescription migraine therapies comprises an array of acute and prophylactic treatments and fosters a large and dynamic pipeline. In the acute space, we anticipate the launch of seve...

    View Details

    Migraine - Geographic Focus: China - Migraine - China In-Depth (China)

    Migraine presents a major public health burden in China, leading to impaired quality of life, widespread health loss, and loss of productivity for a sizeable population. Owing to migraine’s n...

    View Details

    Migraine - Current Treatment - Detailed, Expanded Analysis (EU5)

    According to DRG epidemiology, over 30 million people in the EU5 suffer migraines and over 10% of migraineurs suffer chronic migraine. Migraine prophylaxis is a core treatment approach for high-fre...

    View Details